Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
May 9, 2016 7:30 AM EDTPhase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma
First-in-Human Study Initiated with Second-Generation SINE Compound KPT-8602 in Multiple Myeloma
Phase 2 Clinical Data in Multiple Myeloma Expected Mid-Year
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2016 and commented on recent accomplishments and clinical development plans for its pipeline... More
